Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.6301
+0.0101 (1.63%)
At close: Jun 5, 2025, 4:00 PM
0.6103
-0.0198 (-3.14%)
After-hours: Jun 5, 2025, 5:23 PM EDT

Cue Biopharma Statistics

Total Valuation

Cue Biopharma has a market cap or net worth of $47.48 million. The enterprise value is $40.55 million.

Market Cap 47.48M
Enterprise Value 40.55M

Important Dates

The last earnings date was Monday, May 12, 2025, after market close.

Earnings Date May 12, 2025
Ex-Dividend Date n/a

Share Statistics

Cue Biopharma has 75.35 million shares outstanding. The number of shares has increased by 33.15% in one year.

Current Share Class 75.35M
Shares Outstanding 75.35M
Shares Change (YoY) +33.15%
Shares Change (QoQ) +0.02%
Owned by Insiders (%) 0.35%
Owned by Institutions (%) 16.63%
Float 75.08M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 4.85
Forward PS 8.83
PB Ratio 5.82
P/TBV Ratio 7.21
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 5.07
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.03, with a Debt / Equity ratio of 1.08.

Current Ratio 1.03
Quick Ratio 0.91
Debt / Equity 1.08
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -60.36

Financial Efficiency

Return on equity (ROE) is -221.66% and return on invested capital (ROIC) is -90.82%.

Return on Equity (ROE) -221.66%
Return on Assets (ROA) -67.62%
Return on Invested Capital (ROIC) -90.82%
Return on Capital Employed (ROCE) -610.18%
Revenue Per Employee $194,902
Profits Per Employee -$989,854
Employee Count 41
Asset Turnover 0.21
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -59.61% in the last 52 weeks. The beta is 1.42, so Cue Biopharma's price volatility has been higher than the market average.

Beta (5Y) 1.42
52-Week Price Change -59.61%
50-Day Moving Average 0.74
200-Day Moving Average 1.04
Relative Strength Index (RSI) 39.10
Average Volume (20 Days) 169,437

Short Selling Information

The latest short interest is 892,678, so 1.18% of the outstanding shares have been sold short.

Short Interest 892,678
Short Previous Month 867,049
Short % of Shares Out 1.18%
Short % of Float 1.19%
Short Ratio (days to cover) 5.81

Income Statement

In the last 12 months, Cue Biopharma had revenue of $7.99 million and -$40.58 million in losses. Loss per share was -$0.65.

Revenue 7.99M
Gross Profit -26.65M
Operating Income -41.22M
Pretax Income -49.97M
Net Income -40.58M
EBITDA -40.83M
EBIT -41.22M
Loss Per Share -$0.65
Full Income Statement

Balance Sheet

The company has $14.05 million in cash and $7.13 million in debt, giving a net cash position of $6.92 million or $0.09 per share.

Cash & Cash Equivalents 14.05M
Total Debt 7.13M
Net Cash 6.92M
Net Cash Per Share $0.09
Equity (Book Value) 6.58M
Book Value Per Share 0.11
Working Capital 433,000
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$34.72 million and capital expenditures -$161,000, giving a free cash flow of -$34.88 million.

Operating Cash Flow -34.72M
Capital Expenditures -161,000
Free Cash Flow -34.88M
FCF Per Share -$0.46
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -515.88%
Pretax Margin -507.87%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Cue Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -33.15%
Shareholder Yield -33.15%
Earnings Yield -85.49%
FCF Yield -73.47%

Analyst Forecast

The average price target for Cue Biopharma is $3.00, which is 376.12% higher than the current price. The consensus rating is "Strong Buy".

Price Target $3.00
Price Target Difference 376.12%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) -1.08%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Cue Biopharma has an Altman Z-Score of -25.42 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -25.42
Piotroski F-Score 3